Kras-targeting pill doubles survival in metastatic pancreatic cancer, experts say
A daily pill called daraxonrasib doubled median survival in a 500-patient trial of metastatic pancreatic cancer, from about 6.5–6.7 months with chemotherapy to 13.2 months, and it had fewer side effects. The drug inhibits Kras, a common cancer driver, and experts call the results landscape-changing and potentially game-changing, though access to the drug remains a key challenge.